Weekly Bristol-Myers Squibb Company (NYSE:BMY) Ratings

May 3, 2018 - By Mark Williams

Bristol-Myers Squibb Company (NYSE:BMY) Corporate Logo
During 2017 Q4 the big money sentiment decreased to 0.94. That’s change of 0.09, from 2017Q3’s 1.03. 72 investors sold all, 526 reduced holdings as Bristol-Myers Squibb Company ratio is negative. 457 grew positions while 106 funds amassed positions. Funds hold 1.11 billion shares thus 0.48% more from 2017Q3’s 1.11 billion shares.
Peddock Capital Advisors Limited Liability Corp has 8,095 shs. Roof Eidam & Maycock Adv reported 0.19% of its capital in Bristol-Myers Squibb Company (NYSE:BMY). 32,790 were reported by Longer Investments Incorporated. Supplemental Annuity Collective Trust Of Nj accumulated 24,000 shs. 5,538 are held by Patten Grp Inc. Baldwin Brothers Incorporated Ma accumulated 1,702 shs. Stralem Incorporated has 40,900 shs for 0.43% of their capital. Union Bancorporation reported 0.07% in Bristol-Myers Squibb Company (NYSE:BMY). Texas-based Beacon Fincl has invested 0.72% in Bristol-Myers Squibb Company (NYSE:BMY). Prudential Public Limited Company reported 18,419 shs. Howe & Rusling holds 8,600 shs. Drexel Morgan owns 9,298 shs. 50,000 are owned by Iguana Healthcare Management Ltd Liability Corp. Johnson Finance Grp holds 10,771 shs. Coho holds 0.02% in Bristol-Myers Squibb Company (NYSE:BMY) or 11,100 shs.

Bristol-Myers Squibb Company registered $85,985 net activity with 1 buying transaction and 1 insider sale since December 12, 2017. Lynch Thomas J. Jr. had sold 5,300 shs worth $335,172.

Bristol-Myers Squibb Company (NYSE:BMY) Ratings Coverage

Total analysts of 11 have positions in Bristol Myers (NYSE:BMY) as follows: 4 rated it a “Buy”, 0 with “Sell” and 7 with “Hold”. The positive are 36%. The firm has $78.0 highest while $47 is the lowest target. The average target $65.56 is 27.30% above the last ($51.5) price. Since November 13, 2017 according to StockzIntelligence Inc Bristol Myers has 19 analyst reports. On Tuesday, April 17 the company was maintained by Bank of America. On Tuesday, February 6 Leerink Swann maintained Bristol-Myers Squibb Company (NYSE:BMY) with “Buy” rating. On Monday, November 13 the firm earned “Sell” rating by BMO Capital Markets. The stock rating was maintained by Jefferies with “Hold” on Friday, March 23. In Friday, April 20 report Cowen & Co maintained the stock with “Hold” rating. On Tuesday, April 17 the stock of Bristol-Myers Squibb Company (NYSE:BMY) has “Equal-Weight” rating given by Morgan Stanley. On Friday, April 27 the firm has “Market Perform” rating by BMO Capital Markets given. On Wednesday, February 28 the stock has “Hold” rating by DZ Bank. On Friday, February 16 Citigroup maintained Bristol-Myers Squibb Company (NYSE:BMY) rating. Citigroup has “Buy” rating and $78.0 target. In Monday, February 26 report Jefferies maintained the stock with “Hold” rating. Listed here are Bristol-Myers Squibb Company (NYSE:BMY) PTs and latest ratings.

26/04/2018 Broker: Barclays Capital Rating: Hold New Target: $55.0000
27/04/2018 Broker: BMO Capital Markets Old Rating: Underperform New Rating: Market Perform Old Target: $47 Upgrade
20/04/2018 Broker: Cowen & Co Rating: Hold New Target: $60.0000 Maintain
18/04/2018 Broker: BMO Capital Markets Old Rating: Underperform New Rating: Underperform Old Target: $51 New Target: $47 Maintain
17/04/2018 Broker: Bank of America Old Rating: Neutral New Rating: Neutral Old Target: $68 New Target: $61 Maintain
17/04/2018 Broker: Guggenheim Rating: Buy New Target: $72.0000 Maintain
17/04/2018 Broker: Morgan Stanley Old Rating: Overweight New Rating: Equal-Weight Downgrade
13/04/2018 Broker: Jefferies Rating: Hold New Target: $66.0000 Maintain
23/03/2018 Broker: Jefferies Rating: Hold New Target: $70.0000 Maintain
20/03/2018 Broker: J.P. Morgan Rating: Buy New Target: $75.0

BMY is touching $51.5 during the last trading session, after decreased 2.26%.Bristol-Myers Squibb Company has volume of 8.25M shares. Since May 3, 2017 BMY has risen 11.37% and is uptrending. BMY underperformed the S&P 500 by 0.18%.

Bristol-Myers Squibb Company discovers, develops, licenses, makes, markets, and distributes biopharmaceutical products worldwide.The firm is worth $84.20 billion. The firm offers chemically-synthesized drug and biologic in various therapeutic areas, such as oncology; cardiovascular; immunoscience; and virology comprising human immunodeficiency virus infection .The P/E ratio is 84.43. The Company’s products include Empliciti, a humanized monoclonal antibody to treat multiple myeloma; Opdivo, a human monoclonal antibody to treat renal cell carcinoma, non-small cell lung cancer, classical Hodgkin lymphoma, gastric cancer, melanoma, metastatic urothelial carcinoma, and squamous cell carcinoma of the head and neck; Erbitux, an IgG1 monoclonal antibody that blocks the epidermal growth factor receptor; Sprycel, a tyrosine kinase inhibitor for the treatment of adults with Philadelphia chromosome-positive chronic myeloid leukemia; and Yervoy, a monoclonal antibody for metastatic melanoma.

Bristol-Myers Squibb Company (NYSE:BMY) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.